Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease

D Goldblatt, G Alter, S Crotty… - Immunological reviews, 2022 - Wiley Online Library
Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection

A Zhang, HD Stacey, MR D'Agostino, Y Tugg… - Nature Reviews …, 2023 - nature.com
Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

COVID-19: Transmission, prevention, and potential therapeutic opportunities

M Lotfi, MR Hamblin, N Rezaei - Clinica chimica acta, 2020 - Elsevier
The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense …

The role of IgG Fc receptors in antibody-dependent enhancement

S Bournazos, A Gupta, JV Ravetch - Nature Reviews Immunology, 2020 - nature.com
Antibody-dependent enhancement (ADE) is a mechanism by which the pathogenesis of
certain viral infections is enhanced in the presence of sub-neutralizing or cross-reactive non …

[HTML][HTML] Deployment of convalescent plasma for the prevention and treatment of COVID-19

EM Bloch, S Shoham, A Casadevall… - The Journal of …, 2020 - Am Soc Clin Investig
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

CG Rappazzo, LV Tse, CI Kaku, D Wrapp, M Sakharkar… - Science, 2021 - science.org
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population
underscores the need for broadly active countermeasures. We employed a directed …

An update on current therapeutic drugs treating COVID-19

R Wu, L Wang, HCD Kuo, A Shannar, R Peter… - Current pharmacology …, 2020 - Springer
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …

Protocol and reagents for pseudoty** lentiviral particles with SARS-CoV-2 spike protein for neutralization assays

KHD Crawford, R Eguia, AS Dingens, AN Loes… - Viruses, 2020 - mdpi.com
SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing
antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated …

Potential therapeutic options for COVID-19: an update on current evidence

Z Niknam, A Jafari, A Golchin, F Danesh Pouya… - European journal of …, 2022 - Springer
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

AM Arvin, K Fink, MA Schmid, A Cathcart, R Spreafico… - Nature, 2020 - nature.com
Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …